Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | CSF1R | P07333 | 2/20 | 0.33 |
| ▸ | MAT2A | P31153 | 8/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23601040 | 0.91 | FNTA (0.34) | EGFRCSF1RMAT2AFNTAFNTB | |
| SCHEMBL23601286 | 0.89 | FNTA (0.36) | EGFRCSF1RMAT2AFNTAFNTB | |
| SCHEMBL23601039 | 0.89 | PTGES (0.36) | EGFRCSF1RMAT2AFNTAFNTB | |
| SCHEMBL23601404 | 0.88 | FNTA (0.32) | MAT2AFNTAFNTBPRMT5CYP1A2 | |
| SCHEMBL23600993 | 0.88 | FNTA (0.34) | MAT2AFNTAFNTBPRMT5CYP1A2 | |
| SCHEMBL23576987 | 0.88 | FNTA (0.32) | MAT2AFNTAFNTBPRMT5CYP1A2 | |
| SCHEMBL23601829 | 0.88 | MAP3K14 (0.32) | EGFRCSF1RMAT2AFNTAFNTB | |
| SCHEMBL23601649 | 0.87 | PTGDR2 (0.35) | MAT2AFNTAFNTBPRMT5CYP1A2 | |
| SCHEMBL23601290 | 0.86 | FNTA (0.32) | FNTAFNTB | |
| SCHEMBL29909004 | 0.86 | FNTA (0.32) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | EGFR 1239/4885CSF1R 2614/4885MAT2A 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.